Source: Reuters Ireland-based Jazz Pharmaceuticals Plc will buy U.S.-based Celator Pharmaceuticals Inc in a cash deal valued at about $1.5 billion, to gain access to an investigational product in development for treating acute myeloid leukemia. Jazz Pharmaceuticals will pay $30.25 per share in cash for Celator, a 72.6 percent premium…...